3L in CLL: The Best Options in a Patient Double-Refractory to Covalent BTKi and to BCL-2 Inhibitor

284 views
July 11, 2024

Chapters

Exploring Third-Line CLL Treatment

00:00

Sequencing Treatment After BTK Inhibitor Failure

05:47

0 Comments
Login to view comments. Click here to Login